CA3081752A1 - Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes - Google Patents

Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes Download PDF

Info

Publication number
CA3081752A1
CA3081752A1 CA3081752A CA3081752A CA3081752A1 CA 3081752 A1 CA3081752 A1 CA 3081752A1 CA 3081752 A CA3081752 A CA 3081752A CA 3081752 A CA3081752 A CA 3081752A CA 3081752 A1 CA3081752 A1 CA 3081752A1
Authority
CA
Canada
Prior art keywords
protein
subject
peripheral
score
protein markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3081752A
Other languages
English (en)
French (fr)
Inventor
Rhonda Fay RHYNE
Craig Agamemnon MAGARET
Grady Barnes
James Louis JANUZZI
John STROBECK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prevencio Inc
Original Assignee
Prevencio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prevencio Inc filed Critical Prevencio Inc
Publication of CA3081752A1 publication Critical patent/CA3081752A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CA3081752A 2017-11-02 2018-11-02 Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes Pending CA3081752A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580916P 2017-11-02 2017-11-02
US62/580,916 2017-11-02
PCT/US2018/059080 WO2019090166A1 (en) 2017-11-02 2018-11-02 Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes

Publications (1)

Publication Number Publication Date
CA3081752A1 true CA3081752A1 (en) 2019-05-09

Family

ID=66332348

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3081752A Pending CA3081752A1 (en) 2017-11-02 2018-11-02 Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes

Country Status (5)

Country Link
US (1) US20220229071A1 (https=)
EP (1) EP3704491A4 (https=)
JP (1) JP7372251B2 (https=)
CA (1) CA3081752A1 (https=)
WO (1) WO2019090166A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11657921B2 (en) 2019-09-18 2023-05-23 Tempus Labs, Inc. Artificial intelligence based cardiac event predictor systems and methods
CN111803064A (zh) * 2020-06-22 2020-10-23 燕山大学 基于eeg和血清炎症因子分析脑损伤标志物的方法
WO2022060883A1 (en) * 2020-09-16 2022-03-24 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Diagnostic methods for kawasaki disease
WO2022066745A1 (en) * 2020-09-22 2022-03-31 Ohio State Innovation Foundation Methods, compositions, and kits for detecting and measuring endothelial injury in normal and diseased human central nervous system (cns)
EP4346564A4 (en) * 2021-05-28 2025-02-19 Tempus AI, Inc. Ecg-based cardiovascular disease detection systems and related methods
JP7837065B2 (ja) * 2021-06-01 2026-03-30 ザ ユニバーシティ オブ ホンコン 非アルコール性脂肪性肝疾患のための線維症バイオマーカー
US20240266008A1 (en) * 2023-02-01 2024-08-08 Unlearn.AI, Inc. Systems and Methods for Designing Augmented Randomized Trials
CN115938590B (zh) * 2023-02-09 2023-05-02 四川大学华西医院 结直肠癌术后lars预测模型的构建方法及预测系统
KR20250031367A (ko) * 2023-08-28 2025-03-07 고려대학교 산학협력단 동맥경화증 진단용 엑소좀 유래 바이오 마커
CN117031042B (zh) * 2023-09-05 2024-05-31 上海爱谱蒂康生物科技有限公司 用于筛查诊断先天性心脏病胎儿的生物标志物及其应用
CN117393171B (zh) * 2023-12-11 2024-02-20 四川大学华西医院 直肠癌术后lars发展轨迹预测模型构建方法及系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008020B2 (en) * 2004-06-03 2011-08-30 Vermillion, Inc. Biomarkers for peripheral artery disease
WO2007123708A2 (en) * 2006-03-31 2007-11-01 Epitome Biosystems, Inc. Post translational modification pattern analysis
WO2008057806A1 (en) * 2006-11-01 2008-05-15 Vermillion, Inc. A panel of biomarkers for peripheral arterial disease
WO2009003142A1 (en) * 2007-06-27 2008-12-31 The Board Of Trustees Of The Leland, Stanford Junior University Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease
EP2462437A4 (en) * 2009-08-07 2013-01-30 Rules Based Medicine Inc METHOD AND DEVICES FOR DETECTING DIABETIC NEPHROPATHY AND ASSOCIATED DISEASES THEREOF
CN102762743A (zh) * 2009-12-09 2012-10-31 阿维埃尔公司 用于心血管疾病的诊断和分类的生物标记物检验
WO2015006713A1 (en) * 2013-07-12 2015-01-15 Emory University Diagnostic assay to predict cardiovascular risk
JP6788879B2 (ja) * 2015-06-24 2020-11-25 国立研究開発法人理化学研究所 末梢動脈疾患検査方法及び検査用試薬
EP3411720B1 (en) * 2016-02-01 2025-04-16 Prevencio, Inc. Diagnostic and prognostic methods for cardiovascular diseases and events

Also Published As

Publication number Publication date
JP7372251B2 (ja) 2023-10-31
WO2019090166A1 (en) 2019-05-09
EP3704491A1 (en) 2020-09-09
JP2021502573A (ja) 2021-01-28
US20220229071A1 (en) 2022-07-21
EP3704491A4 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
US12146888B2 (en) Diagnostic methods for cardiovascular diseases
US20220229071A1 (en) Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes
US20260029410A1 (en) Prognostic and diagnostic methods for risk of acute kidney injury
JP6944449B2 (ja) 対象の細胞外液量状態のマーカーとしてのＭＲ−ｐｒｏＡＤＭ
CN105556308B (zh) 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物
US20070269836A1 (en) Methods and compositions for the diagnosis of venous thromboembolic disease
JP2009510478A (ja) 全身性炎症反応症候群の診断および／または予後診断のための方法および組成物
EP3497450B1 (en) Histones and/or proadm as markers indicating organ dysfunction
US20110270530A1 (en) Combined natriuretic peptide assays
WO2004058055A2 (en) Method and system for disease detection using marker combinations
EP2875347B1 (en) Methods for diagnosis of sepsis
US20230358762A1 (en) Diagnostic methods for kawasaki disease
US20160282344A1 (en) Methods and compositions for diagnosis and prognosis of sepsis
HK40127526A (en) Diagnostic and prognostic methods for cardiovascular diseases and events
HK1261993B (en) Diagnostic and prognostic methods for cardiovascular diseases and events
HK1261993A1 (en) Diagnostic and prognostic methods for cardiovascular diseases and events
HK40074056A (en) Diagnostic and prognostic methods for cardiovascular diseases and events
CA3033102C (en) Histones and/or proadm as markers indicating organ dysfunction

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231102

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241024

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241127

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250327